The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
 
Louise Emmett
Honoraria - AstraZeneca; Janssen Oncology; Mundipharma
Consulting or Advisory Role - Noxopharm
Speakers' Bureau - Janssen Oncology; Janssen Oncology; Mundipharma
Research Funding - Novartis (Inst); Novartis (Inst); Noxopharm (Inst); Noxopharm (Inst)
 
Shalini Subramaniam
No Relationships to Disclose
 
Alison Yan Zhang
Honoraria - Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Mundipharma; Pfizer (Inst)
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen
 
Andrew James Martin
No Relationships to Disclose
 
Sonia Yip
No Relationships to Disclose
 
Megan Crumbaker
No Relationships to Disclose
 
Nisha Rana
No Relationships to Disclose
 
Kate Ford
No Relationships to Disclose
 
Ailsa Langford
No Relationships to Disclose
 
Roslyn J. Francis
No Relationships to Disclose
 
Michael S Hofman
Consulting or Advisory Role - Endocyte; Janssen
Research Funding - Endocyte (Inst)
Travel, Accommodations, Expenses - Genzyme; Ipsen; Janssen
 
Anthony M. Joshua
Consulting or Advisory Role - AstraZeneca (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Shahneen Kaur Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Arun Azad
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Merck Serono; Novartis; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); MedImmune (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Janssen; Merck Serono; Sanofi
 
Craig Gedye
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Novotech; Pfizer (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Astellas Pharma (Inst); Astellas Pharma (Inst); Merck Sharp & Dohme (Inst)
 
Margaret Mary McJannett
No Relationships to Disclose
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.